Prism Biolab Co (TSE:206A) EBITDA Margin %: -249.52% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:206A Prism Biolab Co Ltd TSE:206A
11 GF Score
Price 円144.00
! 2 Warning Signs
View Full Analysis

What is Prism Biolab Co EBITDA Margin %?

Prism Biolab Co TSE:206A -1.37% 11 EBITDA Margin % is -249.52% as of Mar. 2026. GuruFocus rates TSE:206A with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 939 Biotechnology companies, Prism Biolab Co ranks worse than 55.59% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Prism Biolab Co's EBITDA for the three months ended in Mar. 2026 was 円-300.2 Mil. Prism Biolab Co's Revenue for the three months ended in Mar. 2026 was 円120.3 Mil. Therefore, Prism Biolab Co's EBITDA margin for the quarter that ended in Mar. 2026 was -249.52%.

Prism Biolab Co  (TSE:206A) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Prism Biolab Co EBITDA Margin % Related Terms

Prism Biolab Co EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Prism Biolab Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prism Biolab Co EBITDA Margin % Chart

Prism Biolab Co Annual Data
Trend Sep22 Sep23 Sep24 Sep25
EBITDA Margin %
12.25 -432.26 -256.00 -114.34

Prism Biolab Co Quarterly Data
Sep22 Sep23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -321.66 -5.70 -214.20 -249.52

TSE:206A vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Prism Biolab Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prism Biolab Co EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prism Biolab Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Prism Biolab Co's EBITDA Margin % falls into.


TSE:206A
11GF Score
Prism Biolab Co Ltd TSE:206A
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prism Biolab Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Prism Biolab Co's EBITDA Margin % for the fiscal year that ended in Sep. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=-774.453/677.33
=-114.34 %

Prism Biolab Co's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-300.152/120.29
=-249.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -249.52% mean?
Prism Biolab Co (TSE:206A) has a EBITDA Margin % of -249.52% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Prism Biolab Co and its competitors. According to the industry distribution chart, Prism Biolab Co ranks #522 out of 939 companies in the Biotechnology industry, placing it in the top 55.6%.
Is Prism Biolab Co's EBITDA Margin % too high?
Prism Biolab Co's current EBITDA Margin % is -249.52%. Based on the distribution chart, Prism Biolab Co ranks #522 out of 939 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Prism Biolab Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Prism Biolab Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Prism Biolab Co ranks #522 out of 939 companies for EBITDA Margin %. This places Prism Biolab Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Prism Biolab Co and its competitors. Prism Biolab Co's current EBITDA Margin % is -249.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prism Biolab Co stock overvalued right now?
Prism Biolab Co (TSE:206A) has a current EBITDA Margin % of -249.52%. The current EBITDA Margin % is -249.52%. Prism Biolab Co's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Prism Biolab Co (TSE:206A), the current EBITDA Margin % is -249.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Prism Biolab Co Business Description

Address 26-1, Muraoka-Higashi 2-chome, Kanagawa Prefecture, Fujisawa, JPN, 251-8555
Prism Biolab Co Ltd is engaged in drug discovery and development based on PepMetics Technology, a proprietary platform technology.
11GF Score

Get the complete analysis for TSE:206A

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円144.00
Price